Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

32.3K
Overview
32.3K
Vaccinations01:51

Vaccinations

49.7K
Overview
49.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gold(III) Semiquinone Complexes: Synthesis, Structure, and Application in Photocatalysis.

Angewandte Chemie (International ed. in English)·2026
Same author

CCHFV GP38 and GP85 interact with cell-surface glycosaminoglycans.

Npj viruses·2026
Same author

Polycaprolactone-Itaconic Acid Resins for Additive Manufacturing of Environmentally Degradable 3D and 4D Materials by Thiol-ene Photopolymerization.

Macromolecules·2026
Same author

Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.

Antiviral research·2025
Same author

Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.

Communications biology·2025
Same author

Multifaceted activation of STING axis upon Nipah and measles virus-induced syncytia formation.

PLoS pathogens·2024

Related Experiment Video

Updated: Dec 2, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.8K

[Ebola, the first vaccines available].

Baptiste Martin1, Viktor Volchkov1, Olivier Reynard1

  • 1CIRI, Centre international de recherche en infectiologie, équipe Bases moléculaires de la pathogénicité virale, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.

Medecine Sciences : M/S
|November 5, 2020
PubMed
Summary

Two Ebola virus vaccines are now approved and used in the Democratic Republic of Congo. This review covers vaccine candidates, clinical trials, and field results for Ebola virus prevention.

More Related Videos

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.4K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.5K

Related Experiment Videos

Last Updated: Dec 2, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.8K
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.4K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.5K

Area of Science:

  • Virology
  • Epidemiology
  • Vaccinology

Background:

  • Ebola virus outbreaks have caused major epidemics in recent years.
  • Significant research has focused on developing and evaluating Ebola virus vaccine candidates.
  • The Democratic Republic of Congo is currently using two approved vaccines against the virus.

Purpose of the Study:

  • To review diverse Ebola virus vaccine candidates.
  • To summarize clinical trials conducted for these vaccines.
  • To present initial field results and efficacy data.

Main Methods:

  • Literature review of published studies on Ebola virus vaccines.
  • Analysis of clinical trial data from various vaccine development programs.
  • Examination of epidemiological data and vaccine deployment reports.

Main Results:

  • Several vaccine candidates have progressed through development and evaluation.
  • Two vaccines have received approval and are actively used in affected regions.
  • Initial field data indicate the effectiveness of deployed vaccines in controlling outbreaks.

Conclusions:

  • The development of effective Ebola virus vaccines represents a major scientific advancement.
  • Ongoing vaccination efforts are crucial for managing and preventing future Ebola epidemics.
  • Continued research and surveillance are necessary to combat the evolving threat of Ebola virus.